Literature DB >> 156380

Interactions among the cannabinoids in the antagonism of the abdominal constriction response in the mouse.

J Sanders, D M Jackson, G A Starmer.   

Abstract

The ability of delta 9-tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), 11-OH THC and 8 alpha, 11-diOH THC to antagonise the abdominal constriction response in the mouse induced by formic acid, phenylquinone, 5-hydroxytryptamine, prostaglandin E1 (PGE1) and bradykinin was tested. THC was an effective antagonist against all nociceptive agents with an ED50 in all cases between 1.0 and 2.6 mg/kg. CBN, while also effective against all nociceptive agents, was less potent than THC, with an ED50 range between 46.2 and 112.5 mg/kg. CBD in doses as high as 200 mg/kg was without effect. Using PGE1 as the nociceptive agent, 11-OH THC was equipotent to THC while 8 alpha, 11-diOH THC was inactive. Naloxone, while able to antagonise the antinociceptive effect of morphine against formic acid-induced writhing, did not reverse the antinociceptive effects of THC. There were no pharmacological interactions between THC, CBD and CBN.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 156380     DOI: 10.1007/bf00432273

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  24 in total

1.  Pharmacologic interaction between cannabinol and delta9-tetrahydrocannabinol.

Authors:  R N Takahashi; I G Karniol
Journal:  Psychopharmacologia       Date:  1975

2.  The effect of delta9-tetrahydrocannabinol, cannabidiol and cannabinol on ether anaesthesia in mice.

Authors:  R Malor; D M Jackson; G B Chesher
Journal:  J Pharm Pharmacol       Date:  1975-08       Impact factor: 3.765

3.  Comparative studies in man and in laboratory animals on 8 - and 9 -trans-tetrahydrocannabinol.

Authors:  I G Karniol; E A Carlini
Journal:  Pharmacology       Date:  1973       Impact factor: 2.547

4.  Contribution of the metabolite 7-hydroxy-delta1-tetrahydrocannabinol towards the pharmacological activity of delta 1-tetrahydrocannabinol in mice.

Authors:  E W Gill; G Jones; D K Lawrence
Journal:  Biochem Pharmacol       Date:  1973-01-15       Impact factor: 5.858

5.  Antipyretic, analgesic and anti-inflammatory effects of delta 9-tetrahydrocannabinol in the rat.

Authors:  D S Kosersky; W L Dewey; L S Harris
Journal:  Eur J Pharmacol       Date:  1973-10       Impact factor: 4.432

6.  Interaction of delta9-tetrahydrocannabinol and cannabidiol on intestinal motility in mice.

Authors:  P F Anderson; D M Jackson; G B Chesher
Journal:  J Pharm Pharmacol       Date:  1974-02       Impact factor: 3.765

7.  Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats.

Authors:  R D Sofia; H B Vassar; L C Knobloch
Journal:  Psychopharmacologia       Date:  1975

8.  The interaction between prostaglandin E1 and delta 9-tetrahydrocannabinol on intestinal motility and on the abdominal constriction response in the mouse.

Authors:  D M Jackson; R Malor; G B Chesher; G A Starmer; P J Welburn; R Bailey
Journal:  Psychopharmacologia       Date:  1976-05-28

9.  Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin.

Authors:  G B Chesher; D M Jackson
Journal:  Psychopharmacologia       Date:  1974-07-11

10.  Activity of delta8- and delta9-tetrahydrocannabinol and related compounds in the mouse.

Authors:  H D Christensen; R I Freudenthal; J T Gidley; R Rosenfeld; G Boegli; L Testino; D R Brine; C G Pitt; M E Wall
Journal:  Science       Date:  1971-04-09       Impact factor: 47.728

View more
  13 in total

1.  Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.

Authors:  Jose Cumella; Laura Hernández-Folgado; Rocio Girón; Eva Sánchez; Paula Morales; Dow P Hurst; Maria Gómez-Cañas; Maria Gómez-Ruiz; Diana C G A Pinto; Pilar Goya; Patricia H Reggio; María Isabel Martin; Javier Fernández-Ruiz; Artur M S Silva; Nadine Jagerovic
Journal:  ChemMedChem       Date:  2012-02-02       Impact factor: 3.466

2.  Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity.

Authors:  Stevie C Britch; Jenny L Wiley; Zhihao Yu; Brian H Clowers; Rebecca M Craft
Journal:  Drug Alcohol Depend       Date:  2017-04-15       Impact factor: 4.492

3.  Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol.

Authors:  Nicholas Z Greene; Jenny L Wiley; Zhihao Yu; Brian H Clowers; Rebecca M Craft
Journal:  Psychopharmacology (Berl)       Date:  2018-09-20       Impact factor: 4.530

4.  Tolerance to, and symmetrical cross-tolerance between, cannabinol and delta 9-tetrahydrocannabinol.

Authors:  B S Fish; P Consroe
Journal:  Experientia       Date:  1981-03-15

5.  Interactions between THC and cannabidiol in mouse models of cannabinoid activity.

Authors:  S A Varvel; J L Wiley; R Yang; D T Bridgen; K Long; A H Lichtman; B R Martin
Journal:  Psychopharmacology (Berl)       Date:  2006-03-30       Impact factor: 4.530

6.  Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.

Authors:  Robert E Vann; Thomas F Gamage; Jonathan A Warner; Ericka M Marshall; Nathan L Taylor; Billy R Martin; Jenny L Wiley
Journal:  Drug Alcohol Depend       Date:  2008-04-01       Impact factor: 4.492

7.  Gonadal hormone modulation of ∆9-tetrahydrocannabinol-induced antinociception and metabolism in female versus male rats.

Authors:  R M Craft; A E Haas; J L Wiley; Z Yu; B H Clowers
Journal:  Pharmacol Biochem Behav       Date:  2016-09-24       Impact factor: 3.533

8.  Analgesic and antiinflammatory activity of constituents of Cannabis sativa L.

Authors:  E A Formukong; A T Evans; F J Evans
Journal:  Inflammation       Date:  1988-08       Impact factor: 4.092

9.  Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain.

Authors:  Stevie C Britch; Alan G Goodman; Jenny L Wiley; Abby M Pondelick; Rebecca M Craft
Journal:  J Pharmacol Exp Ther       Date:  2020-03-16       Impact factor: 4.030

10.  Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw.

Authors:  Barbara Costa; Mariapia Colleoni; Silvia Conti; Daniela Parolaro; Chiara Franke; Anna Elisa Trovato; Gabriella Giagnoni
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.